{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:56:45Z","timestamp":1790780205693,"version":"4.1.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T00:00:00Z","timestamp":1785628800000},"content-version":"am","delay-in-days":335,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004080","name":"Korea Drug Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004080","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020206","name":"Korea Dementia Research Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020206","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NIH National Cancer Institute","doi-asserted-by":"publisher","award":["ZIA SC 006538"],"award-info":[{"award-number":["ZIA SC 006538"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007334","name":"Ministry of Health and Family Welfare","doi-asserted-by":"publisher","award":["RS-2024-00338017"],"award-info":[{"award-number":["RS-2024-00338017"]}],"id":[{"id":"10.13039\/501100007334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003052","name":"Ministry of Trade, Industry and Energy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["AG 000994"],"award-info":[{"award-number":["AG 000994"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010192","name":"Korea Display Research Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010192","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.bbrc.2025.152428","type":"journal-article","created":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T21:06:10Z","timestamp":1754168770000},"page":"152428","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Monoterpenoid fluorophthalimide IMiDs that lack human cereblon binding: synthesis and anti-proliferative, anti-angiogenic and anti-inflammatory activities"],"prefix":"10.1016","volume":"779","author":[{"given":"Weiming","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen M.","family":"Garchitorena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Tweedie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6928-3833","authenticated-orcid":false,"given":"Cindy H.","family":"Chau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0777-7720","authenticated-orcid":false,"given":"Chirag N.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime A.","family":"Siegler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8027-114X","authenticated-orcid":false,"given":"Neil","family":"Vargesson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inho","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soyeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8837-8822","authenticated-orcid":false,"given":"Dong Seok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"Figg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3032-1468","authenticated-orcid":false,"given":"Nigel H.","family":"Greig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2025.152428_bib1","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S0140-6736(61)90927-8","article-title":"Thalidomide and congenital abnormalities (letter)","volume":"2","author":"McBride","year":"1961","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.bbrc.2025.152428_bib2","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1080\/14740338.2021.1991307","article-title":"Thalidomide: history, withdrawal, Renaissance, and safety concerns","volume":"20","author":"Vargesson","year":"2021","journal-title":"Expet Opin. Drug Saf."},{"key":"10.1016\/j.bbrc.2025.152428_bib3","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","article-title":"Thalidomide is an inhibitor of angiogenesis","volume":"91","author":"D'Amato","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"10.1016\/j.bbrc.2025.152428_bib4","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/nrc1323","article-title":"The evolution of thalidomide and its IMiD derivatives as anticancer agents","volume":"4","author":"Bartlett","year":"2004","journal-title":"Nat. Rev. Cancer"},{"issue":"21","key":"10.1016\/j.bbrc.2025.152428_bib5","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbrc.2025.152428_bib6","first-page":"10","article-title":"Cancer statistics","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"issue":"8","key":"10.1016\/j.bbrc.2025.152428_bib7","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.molmed.2024.05.001","article-title":"Immunomodulatory drugs: a promising clinical ally for cancer immunotherapy","volume":"30","author":"Colley","year":"2024","journal-title":"Trends Mol. Med."},{"issue":"8","key":"10.1016\/j.bbrc.2025.152428_bib8","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1093\/jjco\/hyz083","article-title":"Immunomodulatory drugs in the treatment of multiple myeloma","volume":"49","author":"Abe","year":"2019","journal-title":"Jpn. J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.bbrc.2025.152428_bib9","doi-asserted-by":"crossref","first-page":"963","DOI":"10.3390\/cancers15030963","article-title":"Lenalidomide in multiple myeloma: review of resistance mechanisms, current treatment strategies and future perspectives","volume":"15","author":"Kulig","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"5971","key":"10.1016\/j.bbrc.2025.152428_bib10","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1177319","article-title":"Identification of a primary target of thalidomide teratogenicity","volume":"327","author":"Ito","year":"2010","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.bbrc.2025.152428_bib11","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3390\/ph13050095","article-title":"Molecular mechanisms of the teratogenic effects of thalidomide","volume":"13","author":"Asatsuma-Okumura","year":"2020","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bbrc.2025.152428_bib12","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ddtec.2019.02.004","article-title":"Cereblon modulators: low molecular weight inducers of protein degradation","volume":"31","author":"Chamberlain","year":"2019","journal-title":"Drug Discov. Today Technol."},{"issue":"9423","key":"10.1016\/j.bbrc.2025.152428_bib13","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/S0140-6736(04)16308-3","article-title":"Thalidomide","volume":"363","author":"Franks","year":"2004","journal-title":"Lancet."},{"key":"10.1016\/j.bbrc.2025.152428_bib14","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ydbio.2025.03.014","article-title":"Cereblon E3 ligase complex genes are expressed in tissues sensitive to thalidomide in chicken and zebrafish embryos but are unchanged following thalidomide exposure","volume":"522","author":"Fraga","year":"2025","journal-title":"Dev. Biol."},{"key":"10.1016\/j.bbrc.2025.152428_bib15","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1182\/blood-2011-05-356063","article-title":"Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide","volume":"118","author":"Zhu","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2025.152428_bib16","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1182\/blood.2020007081","article-title":"Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma","volume":"137","author":"Gooding","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2025.152428_bib17","doi-asserted-by":"crossref","first-page":"11395","DOI":"10.1096\/fj.201903060RR","article-title":"Role of cereblon in angiogenesis and in mediating the antiangiogenic activity of immunomodulatory drugs","volume":"34","author":"Beedie","year":"2020","journal-title":"FASEB J."},{"key":"10.1016\/j.bbrc.2025.152428_bib18","doi-asserted-by":"crossref","first-page":"5683","DOI":"10.3390\/molecules25235683","article-title":"Antiangiogenic activity and in silico cereblon binding analysis of novel thalidomide analogs","volume":"25","author":"Peach","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.bbrc.2025.152428_bib19","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.bbrc.2020.11.117","article-title":"On the correlation of cereblon binding, fluorination and antiangiogenic properties of immunomodulatory drugs","volume":"534","author":"Heim","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"6","key":"10.1016\/j.bbrc.2025.152428_bib20","doi-asserted-by":"crossref","first-page":"725","DOI":"10.3390\/biom14060725","article-title":"Preclinical evaluation of a novel series of polyfluorinated thalidomide analogs in drug-resistant multiple myeloma","volume":"14","author":"Barton","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.bbrc.2025.152428_bib21","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12929-023-00907-5","article-title":"Novel, thalidomide-like, non-cereblon binding drug tetrafluorobornylphthalimide mitigates inflammation and brain injury","volume":"30","author":"Lecca","year":"2023","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.bbrc.2025.152428_bib22","doi-asserted-by":"crossref","first-page":"11163","DOI":"10.1021\/acsomega.8b00959","article-title":"Chemical ligand space of cereblon","volume":"3","author":"Boichenko","year":"2018","journal-title":"ACS Omega"},{"issue":"12","key":"10.1016\/j.bbrc.2025.152428_bib23","first-page":"3189","article-title":"Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues","volume":"63","author":"Ng","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2025.152428_bib24","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.bbrc.2020.11.117","article-title":"On the correlation of cereblon binding, fluorination and antiangiogenic properties of immunomodulatory drugs","volume":"534","author":"Heim","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbrc.2025.152428_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2024.129858","article-title":"Revisiting the antiangiogenic mechanisms of fluorinated thalidomide derivatives","volume":"110","author":"Sievers","year":"2024","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bbrc.2025.152428_bib26","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.bmc.2003.11.007","article-title":"Thalidomide analogues demonstrate dual inhibition of both angiogenesis and prostate cancer","volume":"12","author":"Capitosti","year":"2004","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bbrc.2025.152428_bib27","doi-asserted-by":"crossref","first-page":"6305","DOI":"10.3390\/molecules17066305","article-title":"Biological activities of alpha-pinene and beta-pinene enantiomers","volume":"17","author":"da Silva","year":"2012","journal-title":"Molecules"},{"issue":"11","key":"10.1016\/j.bbrc.2025.152428_bib28","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3390\/biom9110738","article-title":"Therapeutic potential of \u03b1- and \u03b2-Pinene: a miracle gift of nature","volume":"9","author":"Salehi","year":"2019","journal-title":"Biomolecules"},{"key":"10.1016\/j.bbrc.2025.152428_bib29","series-title":"SHELXL-2018. Program for Crystal Structure Refinement","author":"Sheldrick","year":"2018"},{"issue":"2","key":"10.1016\/j.bbrc.2025.152428_bib30","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jneumeth.2009.06.034","article-title":"A cellular model of inflammation for identifying TNF-Alpha synthesis inhibitors","volume":"183","author":"Tweedie","year":"2009","journal-title":"J. Neurosci. Methods"},{"issue":"10","key":"10.1016\/j.bbrc.2025.152428_bib31","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1212\/01.WNL.0000146196.01316.A2","article-title":"A mutation in a novel ATP-Dependent lon protease gene in a kindred with mild mental retardation","volume":"63","author":"Higgins","year":"2004","journal-title":"Neurology"},{"issue":"15","key":"10.1016\/j.bbrc.2025.152428_bib32","doi-asserted-by":"crossref","first-page":"6234","DOI":"10.1039\/D2CS00116K","article-title":"Discovery of CRBN as a target of thalidomide: a breakthrough for progress in the development of protein degraders","volume":"51","author":"Yamamoto","year":"2022","journal-title":"Chem. Soc. Rev."},{"issue":"9","key":"10.1016\/j.bbrc.2025.152428_bib33","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nsmb.2874","article-title":"Structural basis for responsiveness to thalidomide-analog drugs defined by the crystal structure of the human cereblon:DDB1:lenalidomide complex","volume":"21","author":"Chamberlain","year":"2014","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.bbrc.2025.152428_bib34","first-page":"325","volume":"4","author":"Giuliani","year":"2011","journal-title":"Angiogenesis and multiple myeloma. Cancer Microenviron"},{"key":"10.1016\/j.bbrc.2025.152428_bib35","first-page":"2031","volume":"19","author":"Ribatti","year":"2018","journal-title":"New Insights in Anti-Angiogenesis in Multiple Myeloma. Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2025.152428_bib36","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.reprotox.2016.10.005","article-title":"Arterial dysgenesis and limb defects: clinical and experimental examples","volume":"70","author":"Vargesson","year":"2017","journal-title":"Reprod. Toxicol."},{"issue":"4","key":"10.1016\/j.bbrc.2025.152428_bib37","doi-asserted-by":"crossref","DOI":"10.1002\/bdr2.2465","article-title":"Embryonic vascular dysgenesis: the origin of proximal femoral focal deficiency","volume":"117","author":"Hootnick","year":"2025","journal-title":"Birth Defects Res"},{"key":"10.1016\/j.bbrc.2025.152428_bib38","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1177\/1753193418805249","article-title":"The teratogenic effects of thalidomide on limbs","volume":"44","author":"Vargesson","year":"2019","journal-title":"Hand Surg Eur"},{"issue":"7347","key":"10.1016\/j.bbrc.2025.152428_bib39","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10144","article-title":"Molecular mechanisms and clinical applications of angiogenesis","volume":"473","author":"Carmeliet","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2025.152428_bib40","doi-asserted-by":"crossref","DOI":"10.1007\/s12094-024-03667-2","article-title":"Emerging immunologic approaches as cancer anti-angiogenic therapies","author":"Azimi","year":"2024","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.bbrc.2025.152428_bib41","doi-asserted-by":"crossref","first-page":"8573","DOI":"10.1073\/pnas.0901505106","article-title":"Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation","volume":"106","author":"Therapontos","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"6","key":"10.1016\/j.bbrc.2025.152428_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.109979","article-title":"Hallmarks of cancer resistance","volume":"27","author":"Tufail","year":"2024","journal-title":"iScience"},{"issue":"3","key":"10.1016\/j.bbrc.2025.152428_bib43","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1124\/mol.107.040808","article-title":"Combinatorial antileukemic disruption of oxidative homeostasis and mitochondrial stability by the redox reactive thalidomide 2-(2,4-difluoro-phenyl)-4,5,6,7-tetrafluoro-1H-isoindole-1,3(2H)-dione (CPS49) and flavopiridol","volume":"74","author":"Ge","year":"2008","journal-title":"Mol. Pharmacol."},{"issue":"11","key":"10.1016\/j.bbrc.2025.152428_bib44","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1002\/alz.12610","article-title":"Role of chronic neuroinflammation in neuroplasticity and cognitive function: a hypothesis","volume":"18","author":"Lecca","year":"2022","journal-title":"Alzheimer's Dement."},{"key":"10.1016\/j.bbrc.2025.152428_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2024.129885","article-title":"2-(Piperidin-3-yl)phthalimides reduce classical markers of cellular inflammation in LPS-Challenged RAW 264.7 cells and also demonstrate potentially relevant sigma and serotonin receptor affinity in membrane preparations","volume":"110","author":"Scerba","year":"2024","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"24","key":"10.1016\/j.bbrc.2025.152428_bib46","doi-asserted-by":"crossref","first-page":"5222","DOI":"10.1021\/jm030152f","article-title":"Thiothalidomides: novel isosteric analogues of thalidomide with enhanced TNF-Alpha inhibitory activity","volume":"46","author":"Zhu","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbrc.2025.152428_bib47","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2174\/1874091X01105010037","article-title":"Thalidomide analogues suppress lipopolysaccharide-induced synthesis of TNF-\u03b1 and nitrite, an intermediate of nitric oxide, in a cellular model of inflammation","volume":"5","author":"Tweedie","year":"2011","journal-title":"Open Biochem. J."},{"issue":"1","key":"10.1016\/j.bbrc.2025.152428_bib48","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12929-017-0370-8","article-title":"Comprehensive comparison of three different animal models for systemic inflammation","volume":"24","author":"Seemann","year":"2017","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.bbrc.2025.152428_bib49","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.molmed.2017.02.006","article-title":"A brighter side to thalidomide: its potential use in immunological disorders","volume":"23","author":"Millrine","year":"2017","journal-title":"Trends Mol. Med."},{"issue":"6","key":"10.1016\/j.bbrc.2025.152428_bib50","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/intimm\/dxw005","article-title":"Immunomodulatory drugs inhibit TLR4-induced type-1 interferon production independently of cereblon via suppression of the TRIF\/IRF3 pathway","volume":"28","author":"Millrine","year":"2016","journal-title":"Int. Immunol."},{"issue":"46","key":"10.1016\/j.bbrc.2025.152428_bib51","doi-asserted-by":"crossref","first-page":"11802","DOI":"10.1073\/pnas.1814446115","article-title":"Humanized cereblon mice revealed two distinct therapeutic pathways of immunomodulatory drugs","volume":"115","author":"Gemechu","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"19","key":"10.1016\/j.bbrc.2025.152428_bib52","doi-asserted-by":"crossref","first-page":"7078","DOI":"10.3390\/ijms21197078","article-title":"Monoterpenes and their derivatives-recent development in biological and medical applications","volume":"21","author":"Zieli\u0144ska-B\u0142ajet","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2025.152428_bib53","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.fct.2018.10.058","article-title":"Monoterpenes modulating cytokines - a review","volume":"123","author":"Quintans","year":"2019","journal-title":"Food Chem. Toxicol."},{"issue":"6","key":"10.1016\/j.bbrc.2025.152428_bib54","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1021\/acschemneuro.6b00029","article-title":"Central nervous system multiparameter optimization desirability: application in drug discovery","volume":"7","author":"Wager","year":"2016","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.bbrc.2025.152428_bib55","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.656921","article-title":"Repurposing immunomodulatory imide drugs (IMiDs) in neuropsychiatric and neurodegenerative disorders","volume":"15","author":"Jung","year":"2021","journal-title":"Front. Neurosci."},{"issue":"5","key":"10.1016\/j.bbrc.2025.152428_bib56","doi-asserted-by":"crossref","first-page":"747","DOI":"10.3390\/biom13050747","article-title":"A new generation of IMiDs as treatments for neuroinflammatory and neurodegenerative disorders","volume":"13","author":"Kopp","year":"2023","journal-title":"Biomolecules"}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X2501143X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X2501143X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T04:29:05Z","timestamp":1779769745000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X2501143X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":56,"alternative-id":["S0006291X2501143X"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2025.152428","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Monoterpenoid fluorophthalimide IMiDs that lack human cereblon binding: synthesis and anti-proliferative, anti-angiogenic and anti-inflammatory activities","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2025.152428","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152428"}}